: Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.

Previous post Outside the Box: The enduring value of value investing in stocks, real estate and other assets
Next post : Washington warily eyes the death of the Chinese economic ‘juggernaut’